Zacks Investment Research downgraded shares of Swedish Orphan Bio Spon (NASDAQ:SWTUY) from a buy rating to a hold rating in a research report released on Thursday.
According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “
Shares of Swedish Orphan Bio Spon (SWTUY) opened at 15.72 on Thursday. Swedish Orphan Bio Spon has a 12-month low of $10.25 and a 12-month high of $16.49. The firm has a market capitalization of $4.23 billion and a PE ratio of 54.21. The company has a 50-day moving average price of $15.72 and a 200 day moving average price of $15.04.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Swedish Orphan Bio Spon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Bio Spon and related companies with MarketBeat.com's FREE daily email newsletter.